BRPI0517091B8 - composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida - Google Patents
composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamidaInfo
- Publication number
- BRPI0517091B8 BRPI0517091B8 BRPI0517091A BRPI0517091A BRPI0517091B8 BR PI0517091 B8 BRPI0517091 B8 BR PI0517091B8 BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 B8 BRPI0517091 B8 BR PI0517091B8
- Authority
- BR
- Brazil
- Prior art keywords
- thiocarboxamide
- compound
- carboxamide
- hydroxybenzomorphan
- substituted
- Prior art date
Links
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical group NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 title abstract 2
- 206010012335 Dependence Diseases 0.000 abstract 1
- 102000003840 Opioid Receptors Human genes 0.000 abstract 1
- 108090000137 Opioid Receptors Proteins 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229940125714 antidiarrheal agent Drugs 0.000 abstract 1
- 239000003793 antidiarrheal agent Substances 0.000 abstract 1
- 239000003434 antitussive agent Substances 0.000 abstract 1
- 229940124584 antitussives Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62534804P | 2004-11-05 | 2004-11-05 | |
| US60/625,348 | 2004-11-05 | ||
| PCT/US2005/039911 WO2006052710A1 (en) | 2004-11-05 | 2005-11-03 | 4-hydroxybenzomorphans |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0517091A BRPI0517091A (pt) | 2008-09-30 |
| BRPI0517091B1 BRPI0517091B1 (pt) | 2019-10-08 |
| BRPI0517091B8 true BRPI0517091B8 (pt) | 2021-05-25 |
Family
ID=36128632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0517091A BRPI0517091B8 (pt) | 2004-11-05 | 2005-11-03 | composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida |
Country Status (20)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE292625T1 (de) * | 2000-10-31 | 2005-04-15 | Rensselaer Polytech Inst | 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien |
| US7262298B2 (en) * | 2004-11-05 | 2007-08-28 | Rensselaer Polytechnic Institute | 4-hydroxybenzomorphans |
| AU2006272773B2 (en) | 2005-07-21 | 2012-03-08 | Rensselaer Polytechnic Institute | 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents |
| ATE493416T1 (de) | 2007-05-04 | 2011-01-15 | Mallinckrodt Inc | Verbessertes verfahren zur herstellung von 6- alpha-hydroxy-n-alkylierten opiaten |
| JP2010533719A (ja) | 2007-07-17 | 2010-10-28 | マリンクロッド・インコーポレイテッド | 還元的アミノ化によるｎ−アルキル化オピエートの調製 |
| WO2009023567A1 (en) | 2007-08-09 | 2009-02-19 | Rensselaer Polytechnic Institute | Quaternary opioid carboxamides |
| CA2738628C (en) | 2008-09-30 | 2017-07-04 | Mallinckrodt Inc. | Processes for the selective amination of ketomorphinans |
| US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
| WO2010107457A1 (en) * | 2009-03-19 | 2010-09-23 | Alkermes, Inc. | Morphinan derivatives with high oral bioavailability |
| WO2010118274A1 (en) * | 2009-04-09 | 2010-10-14 | Mallinckrodt Inc. | Preparation of 6-keto, 3-alkoxy morphinans |
| US8471023B2 (en) | 2009-06-11 | 2013-06-25 | Mallinckrodt Llc | Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer |
| CA2764915C (en) | 2009-06-11 | 2017-07-11 | Mallinckrodt Llc | Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer |
| HUE043963T2 (hu) * | 2009-12-04 | 2019-09-30 | Alkermes Pharma Ireland Ltd | Morfinán származékok gyógyszer-túladagolás kezelésére |
| WO2011119605A2 (en) | 2010-03-22 | 2011-09-29 | Rensselaer Polytechnic Institute | Carboxamide biosiosteres of opiates |
| WO2011137086A1 (en) * | 2010-04-29 | 2011-11-03 | Mallinckrodt Llc | Preparation of saturated ketone morphinan compounds having low metal content |
| WO2012005795A1 (en) | 2010-07-08 | 2012-01-12 | Alkermes, Inc. | Process for the synthesis of substituted morphinans |
| EP2608670B1 (en) | 2010-08-23 | 2018-10-31 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
| US9029543B2 (en) | 2011-04-05 | 2015-05-12 | Alkermes, Inc. | Process for the synthesis of quaternary amine compounds |
| ES2698408T3 (es) | 2011-06-09 | 2019-02-04 | SpecGx LLC | Aminación reductora de 6-ceto morfinanos por transferencia de hidrógeno catalítico |
| CA2840643C (en) | 2011-06-29 | 2017-11-21 | Alkermes, Inc. | Peripherally acting opioid compounds |
| KR20140063763A (ko) | 2011-09-08 | 2014-05-27 | 말린크로트 엘엘씨 | 중간체를 단리하지 않는 알칼로이드의 제조 방법 |
| SMT201800664T1 (it) | 2011-12-15 | 2019-01-11 | Alkermes Pharma Ireland Ltd | Samidorphan (alks 33) in combinazione con buprenorfina per il trattamento di disturbi depressivi |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| ES2770978T3 (es) | 2013-05-24 | 2020-07-06 | Alkermes Pharma Ireland Ltd | Análogos de morfanos y morfinanos y métodos de uso |
| US9656961B2 (en) | 2013-05-24 | 2017-05-23 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| KR20190120212A (ko) * | 2017-03-02 | 2019-10-23 | 가부시키가이샤산와카가쿠켄큐쇼 | 알코올 사용 장해의 치료약 |
| CN107089948B (zh) * | 2017-04-28 | 2020-07-17 | 云南大学 | 吗吩衍生物及其制备方法和应用 |
| CN111978252A (zh) * | 2019-05-21 | 2020-11-24 | 复旦大学 | 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用 |
| TW202140009A (zh) * | 2020-02-13 | 2021-11-01 | 大陸商上海翰森生物醫藥科技有限公司 | ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用 |
| CN111205151B (zh) * | 2020-02-29 | 2021-03-05 | 深圳市祥根生物科技有限公司 | 一种布洛芬杂质i的环保制备方法 |
| WO2022101444A1 (en) | 2020-11-12 | 2022-05-19 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| CN114621238B (zh) * | 2020-12-10 | 2026-02-03 | 鲁南制药集团股份有限公司 | 一种制备纳呋拉啡的方法 |
| KR102663533B1 (ko) * | 2021-11-09 | 2024-05-08 | 백미선 | 레이저 치료기기용 온냉각장치 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957793A (en) * | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
| US4032529A (en) * | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
| SU635868A3 (ru) * | 1974-11-12 | 1978-11-30 | Бристол Мейерз Компани (Фирма) | Способ получени морфиновых производных или их солей |
| US4205171A (en) * | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
| US4373139A (en) * | 1979-04-30 | 1983-02-08 | Motorola, Inc. | Detectors |
| US4649200A (en) * | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
| EP0632041A1 (en) | 1993-07-01 | 1995-01-04 | Katholieke Universiteit Nijmegen | New morphine derivatives having improved analgesic and narcotic properties |
| HUP9900974A3 (en) | 1996-01-10 | 2000-09-28 | Smithkline Beecham Spa | Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them |
| ATE292625T1 (de) * | 2000-10-31 | 2005-04-15 | Rensselaer Polytech Inst | 8-substituierte 2,6-methano-3-benzazocine und 3- substituierte morphinane als opioidrezeptorbindende agenzien |
| WO2004007449A1 (en) * | 2002-07-16 | 2004-01-22 | Rensselaer Polytechnic Institute | Process for conversion of phenols to carboxamides via the succinimide esters |
| US7262298B2 (en) * | 2004-11-05 | 2007-08-28 | Rensselaer Polytechnic Institute | 4-hydroxybenzomorphans |
-
2005
- 2005-11-03 US US11/266,651 patent/US7262298B2/en not_active Expired - Lifetime
- 2005-11-03 JP JP2007540055A patent/JP5198067B2/ja not_active Expired - Lifetime
- 2005-11-03 EP EP10008474A patent/EP2251330B1/en not_active Expired - Lifetime
- 2005-11-03 EP EP05851351A patent/EP1817291A1/en not_active Withdrawn
- 2005-11-03 AU AU2005304950A patent/AU2005304950B2/en not_active Expired
- 2005-11-03 BR BRPI0517091A patent/BRPI0517091B8/pt active IP Right Grant
- 2005-11-03 PT PT10008474T patent/PT2251330E/pt unknown
- 2005-11-03 CA CA2587074A patent/CA2587074C/en not_active Expired - Lifetime
- 2005-11-03 AT AT10008474T patent/ATE557006T1/de active
- 2005-11-03 WO PCT/US2005/039911 patent/WO2006052710A1/en not_active Ceased
- 2005-11-03 CN CN2005800451698A patent/CN101090891B/zh not_active Expired - Lifetime
- 2005-11-03 KR KR1020077012582A patent/KR101115841B1/ko not_active Expired - Lifetime
- 2005-11-03 MX MX2007005389A patent/MX2007005389A/es active IP Right Grant
- 2005-11-03 PL PL10008474T patent/PL2251330T3/pl unknown
- 2005-11-03 DK DK10008474.8T patent/DK2251330T3/da active
- 2005-11-03 RU RU2007120759/04A patent/RU2415131C2/ru active
- 2005-11-03 RU RU2010147915/04A patent/RU2480455C2/ru active
- 2005-11-03 SI SI200531549T patent/SI2251330T1/sl unknown
- 2005-11-03 ES ES10008474T patent/ES2387737T3/es not_active Expired - Lifetime
-
2007
- 2007-05-03 IL IL182983A patent/IL182983A/en active IP Right Grant
- 2007-06-04 NO NO20072839A patent/NO340204B1/no unknown
- 2007-06-08 US US11/760,039 patent/US8680112B2/en active Active
-
2012
- 2012-07-31 CY CY20121100677T patent/CY1112946T1/el unknown
- 2012-11-22 JP JP2012256445A patent/JP6058981B2/ja not_active Expired - Lifetime
-
2013
- 2013-04-15 US US13/862,975 patent/US20130231361A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,305 patent/US8802655B2/en not_active Expired - Lifetime
- 2014-07-02 US US14/321,885 patent/US20150011768A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/697,013 patent/US20160075658A1/en not_active Abandoned
- 2015-08-12 JP JP2015159733A patent/JP2016020364A/ja active Pending
-
2023
- 2023-04-17 US US18/301,336 patent/US20240092740A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0517091A (pt) | composto, e, método para tratar uma doença ou condição alterando-se uma resposta mediada por um receptor de opióide | |
| BRPI0408247A (pt) | usos de antagonistas e agonistas de il-23 e reagentes relacionados | |
| ECSP088461A (es) | Composiciones farmacéuticas que contienen buprenorfina | |
| CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
| NO20052739D0 (no) | CCR5-antagonister som medikamenter | |
| BRPI0415361A (pt) | antagonistas do receptor muscarìnico de acetilcolina | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
| MY149803A (en) | Markup based extensibility for user interfaces | |
| MX358592B (es) | Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos. | |
| MX2007012237A (es) | Amilina y agonistas de amilina para tratar enfermedades y trastornos siquiatricos. | |
| BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
| IL189948A0 (en) | Y2 selective receptor agonists for therapeutic interventions | |
| WO2008018796A3 (en) | Viscoelastic aqueous gels comprising microspheres | |
| BRPI0416534A (pt) | composições multiparticuladas com estabilidade melhorada | |
| DE60334379D1 (de) | Copolymerverbindung, diese enthaltende polymerzusammensetzung, bilderzeugungsverfahren und dieselbe benutzende bilderzeugungsvorrichtung | |
| FR2886851B1 (fr) | Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee | |
| BRPI0506888A (pt) | composições de suplemento lìquido compreendendo um ou mais medicamentos | |
| DK1220852T3 (da) | Substituerede diazepaner | |
| BRPI0514074A (pt) | aperfeiçoamentos em composições em bloco para lavatório | |
| BRPI0611526A2 (pt) | composição tópica contendo gelatina | |
| BR0313307A (pt) | Antagonistas do receptor de mcp-1 e método para a sua utilização | |
| FR2886852B1 (fr) | Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee | |
| EA200501818A1 (ru) | Индазолы, обладающие анальгетической активностью | |
| BRPI0414423A (pt) | inibidores de pace4, suas composições farmacêuticas e respectivos usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B15V | Prolongation of time limit allowed |